NCT05326451Recruiting
Home-based Transcranial Direct Current Stimulation Open Trial for Behavioral and Cognitive Symptoms in Huntington's Disease
Source: ClinicalTrials.gov · Last updated 11 Feb 2026
Brief summary (registry, in English)
The purpose of this study is to assess feasibility, acceptability, and safety of providing transcranial direct current stimulation( tDCS) to Huntingtons Disease (HD) patients in the early to middle stages and to assess the efficacy of tDCS for HD-related behavioral, cognitive and other symptoms
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- First submitted
- 5 Apr 2022
- Start date
- 21 Jun 2023
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Diseases
- Huntington's disease
- NCT number
- NCT05326451
What you commit to
- Study type: Interventional
- Planned participants: 10
- From 21 Jun 2023 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Have risk of suicidal behavior, defined as any suicidal behavior or suicidal ideation of type 4 or type 5 based on the Columbia-Suicide Severity Rating Scale (C-SSRS) in the 3 months prior to screening
Other illness
- unstable medical conditions
- history of epilepsy
- clinical diagnosis of major cognitive disorder or dementia
- -motor/cognitive symptoms related to Alzheimer's disease or Huntington's disease that might impair the ability to assist the participant during the research study.
Other
- metallic objects in the brain
- Have a caregiver willing to be present during tDCS sessions and answer questionnaires.
- simultaneous participation in other clinical trial
- Individuals determined to be incapable of consent per past medical history or via assessment by the study staff at time of consent.
- Caregiver:
Who the study is looking for
- confirmed HD mutation carriers and/or established family history alongside typical symptoms (i.e. chorea) of HD;
- early (stages 1 and 2) or moderate (stage 3) stages according to Shoulson-Fahn
- exhibit mild to moderate behavioral symptoms defined by severity scores in the PBA-S between 1 and 3 for any of the evaluated symptoms and no symptoms with a severity score of 4
- stable doses of medications for at least one month
- Have a caregiver willing to be present during tDCS sessions and answer questionnaires.
- -willingness to participate in the study
Criteria the registry did not label
- Participant:
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The University of Texas Health Science Center at Houston Coordinator of this site? Confirm its status | Houston | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.